- Global Pharma News & Resources

Envision Pharma Group appoints Manish Goel as Global Head of Envision Technology Solutions

Envision Pharma Group appoints Manish Goel as Global Head of Envision Technology Solutions


London, UK, March 18, 2021


Leading global technology-enabled scientific communications company Envision Pharma Group (“Envision” or the “Company”) has appointed Manish Goel as its new Global Head of Envision Technology Solutions (ETS) to drive the development of innovative technologies for the life sciences sector.


Manish Goel brings over 15 years of leadership experience across the technology and healthcare sphere, and joins Envision from IQVIA where he served as the VP of Technology Solutions to lead the development of its customer engagement portfolio of technologies. At Envision, he will focus on the continuing transformation of iEnvision – the global medical affairs platform, solidifying its position as the leading Software as a Service (SaaS) platform and driving the development of innovative and differentiating capabilities for the medical affairs organization.

Goel said, “With COVID-19 accelerating the pace of change in the medical affairs landscape, and the critical, enabling role iEnvision can play here for life science companies, this is an exciting time to join Envision as it embarks on its next phase of strategic growth.”

He added, “I look forward to building on the strength of iEnvision’s existing solutions and customer relationships to deliver market-leading capabilities, that further extend our market position within the medical affairs function.”

David Thompson, CEO, Envision, said, “With his technology pedigree, healthcare experience, and impressive track record, we are delighted to have Manish join Envision. As a proven leader, we look forward to embracing his tremendous expertise in writing the next chapter for iEnvision – establishing it as the gold standard for the medical affairs function as we identify, invest, and develop capabilities that enable us to spread beyond our medical affairs client base.”

Editor Details

Last Updated: 19-Mar-2021